机构：[1]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China神经外科普外科苏州大学附属第二医院[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[3]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[4]Brain Tumor Center, Beijing Institute for Brain Disorders, Beijing, China[5]Department of Ophthalmology, School of Medicine, Shandong University, Jinan, China[6]Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China[7]Chinese Glioma Cooperative Group (CGCG), Beijing, China[8]China National Clinical Research Center for Neurological Diseases, Beijing, China
Glioblastoma is the most malignant tumor and has high mortality rate. The methylated prompter of MGMT results in chemotherapy sensitivity for these patients. However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status. We developed a signature with three genes screened from the whole genome mRNA expression profile from Chinese Glioma Genome Atlas (CGGA) and RNAseq data from The Cancer Genome Atlas (TCGA). Patients with MGMT methylation in low risk group had longer survival than those in high risk group (median overall survival 1074 vs. 372 days; P = 0.0033). Moreover, the prognostic value of the signature was significant difference in cohorts stratified by MGMT methylation and chemotherapy (P= 0.0473), while there is no significant difference between low and high risk group or unmethylated MGMT patients without chemotherapy. Multivariate analysis indicated that the risk score was an independent prognosis factor (P = 0.004). In conclusion, our results showed that the signature has prognostic value for patients with MGMT promoter-methylated glioblastomas based on bioinformatics analysis.
基金：
This work was supported by grants from Ministry of Science and Technology of China grant (2012CB825505 and 2011BAI08B08), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B03, 2014BAI04B02), National High Technology Research and Development Program (No.2012AA02A508), National Natural Science Foundation of China (No. 91229121), Beijing Science and Technology Plan (No. Z131100006113018).
第一作者机构：[1]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[3]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[7]Chinese Glioma Cooperative Group (CGCG), Beijing, China
通讯作者：
通讯机构：[1]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[8]China National Clinical Research Center for Neurological Diseases, Beijing, China
推荐引用方式(GB/T 7714)：
Wen Wang,Lu Zhang,Zheng Wang,et al.A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma[J].ONCOTARGET.2016,7(43):69991-69999.doi:10.18632/oncotarget.11726.
APA：
Wen Wang,Lu Zhang,Zheng Wang,Fan Yang,Haoyuan Wang...&Jizong Zhao.(2016).A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.ONCOTARGET,7,(43)
MLA：
Wen Wang,et al."A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma".ONCOTARGET 7..43(2016):69991-69999
医学